Status:
UNKNOWN
Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Brief Summary
To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.
Detailed Description
In a prospective observational study the investigators aim to study the ability of modern antirheumatic treatments to suppress levels of survivin in sera. Rheumatoid arthritis patients scheduled to st...
Eligibility Criteria
Inclusion
- Patients fulfilling the RA classification criteria according to the ACR/EULAR
Exclusion
- Patients at stable/unchanged anti-rheumatic treatment
- Other serious physical or mental illness
- Lack of knowledge in Swedish making answering the questionnaires impossible
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT03440892
Start Date
November 1 2017
End Date
January 1 2025
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept of Rheumatology and Inflammation research
Gothenburg, Sweden